Fifth Feinstein Institutes Bioelectronics Medicine Summit Highlights Innovation and the Future of Science
Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
MANHASSET, NY–(BUSINESS WIRE)–Some of the world’s most influential medical experts, researchers and scientific minds attended the fifth Bioelectronics Medicine Summit, “Bioelectronics Medicine: Today’s Tools, Tomorrow’s Therapies”, organized by the Feinstein Institutes for Medical Research. With Columbia University’s School of Engineering and Applied Sciences, the event was the first in-person summit since the pandemic, which took place Oct. 11-12 at the Garden City Hotel in Garden City, New York, where more than 170 people attended. .
This press release is multimedia. Read the full press release here: https://www.businesswire.com/news/home/20221013005978/en/
Dr. Kevin J. Tracey delivers a keynote address at the Bioelectronics Medicine Summit. (Credit: Feinstein Institutes)
Bioelectronic medicine combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies using computer chips and devices instead of drugs to treat a variety of diseases and conditions through nerve stimulation, including paralysis, arthritis, pulmonary hypertension and inflammatory bowel disease.
“Advances in bioelectronic medicine are accelerating in clinical trials and basic science,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. . “This year’s Summit celebrated the collaboration between biomedical engineers, neuroscientists and molecular biologists that is driving innovative advances in this exciting field.”
Key highlights from the two-day symposium include:
Robert Gaunt, PhD, University of Pittsburgh, discussed translating brain-computer interfaces, the specific needs of patient populations, and identifying key technical, regulatory, and market barriers.
Eric Van Gieson, PhD, Defense Advanced Research Projects Agency, moderated a panel on emerging devices, neural interfaces, and the development of new technologies.
Eric Hudak, PhD, National Institutes of Health, discussed how bioelectronic medicine approaches can be used to treat peripheral organ disorders and target complex disorders of immunity, cardiovascular system, metabolism, and others.
Anil Malhotra, MD, co-director of the Institute for Behavioral Sciences at the Feinstein Institutes, discussed how bioelectronic medicine could help treat neuropsychiatric disorders.
Erika Ross, PhD, R&D Applied Research, described how the use of digital health data from consumer and clinical devices could inform disease biomarkers and improve treatment efficacy, device deployment and trial recruitment.
“It’s exciting to exchange ideas with some of the smartest people leading advances in bioelectronic medicine,” said Yousef Al-Abed, PhD, Summit co-chair and co-director of the Institute of Bioelectronic Medicine, with Lopa Mishra. , MD. “It is important that, collectively, researchers around the world continue to share their knowledge and contribute to the evolution of this promising scientific field. »
Some of the key topics discussed included groundbreaking research involving the development of bioelectronic therapies for brain disorders, new technologies and interfaces for stimulation, biosensing, and the use of data science and machine learning in neural systems. .
The Feinstein Institutes, the world’s scientific home for bioelectronic medicine, continue to invest in bioelectronic medicine. Funded in part by previous state grants, New York State Governor Kathy Hochul recently announced an additional $10 million award to upgrade and create more lab space, hire new scientists, create new jobs and boost research.
In partnership with BioMed Centerpart of Springer Nature, Feinstein Institutes Publish Review Bioelectronic medicine. From biochemistry to mechanical engineering to electrical signaling in the nervous system, the journal is an open access publishing platform that amplifies impactful global research in the burgeoning field of science.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, New York State’s largest health care provider and private employer. Home to 50 research laboratories, 3,000 clinical research studies, and 5,000 researchers and staff, the Feinstein Institutes elevate the level of medical innovation through its five institutes of behavioral sciences, bioelectronic medicine, cancer, innovations and results in health and molecular medicine. We’re making breakthroughs in genetics, oncology, brain research, mental health and autoimmunity, and we’re the world’s scientific leader in bioelectronic medicine, a new field scientist who has the potential to revolutionize medicine. For more information on how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.
Julianne Mosher Allen
Source: The Feinstein Institutes for Medical Research